<code id='5EFF95A258'></code><style id='5EFF95A258'></style>
    • <acronym id='5EFF95A258'></acronym>
      <center id='5EFF95A258'><center id='5EFF95A258'><tfoot id='5EFF95A258'></tfoot></center><abbr id='5EFF95A258'><dir id='5EFF95A258'><tfoot id='5EFF95A258'></tfoot><noframes id='5EFF95A258'>

    • <optgroup id='5EFF95A258'><strike id='5EFF95A258'><sup id='5EFF95A258'></sup></strike><code id='5EFF95A258'></code></optgroup>
        1. <b id='5EFF95A258'><label id='5EFF95A258'><select id='5EFF95A258'><dt id='5EFF95A258'><span id='5EFF95A258'></span></dt></select></label></b><u id='5EFF95A258'></u>
          <i id='5EFF95A258'><strike id='5EFF95A258'><tt id='5EFF95A258'><pre id='5EFF95A258'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          entertainment

          author:explore    - browse:89
          Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT
          Darron Cummings/AP

          A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

          Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

          advertisement

          Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          entertainment